Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)

2024/08/01 by Phillip H. Kuo, Michael J. Morris, Jacob Hesterman +25 · 4 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Prostate Cancer Treatment and Research #Radiopharmaceutical Chemistry and Applications #Cancer, Lipids, and Metabolism

paper · doi:10.1148/radiol.233460

Abstract

Visual 68 Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177 Lu-PSMA-617 therapy in the VISION trial, with higher 68 Ga-PSMA-11 uptake associated with improved outcomes.

Cited by

• Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis
• Imaging the hallmarks of cancer
• Prognostic Value of Cycle 1 SPECT SUV mean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA-617
• Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

Related

• 68 Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study
• Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177 Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
• Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis
• Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
• Prediction of Response to 177 Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC